Valneva (NASDAQ:VALN) Shares Down 3.9%

Shares of Valneva SE (NASDAQ:VALN) fell 3.9% on Friday . The stock traded as low as $7.81 and last traded at $7.81. 1,758 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 9,062 shares. The stock had previously closed at $8.13.

Analyst Ratings Changes

Several research firms have recently weighed in on VALN. HC Wainwright restated a “buy” rating and issued a $26.00 price target on shares of Valneva in a research note on Thursday, March 21st. Guggenheim decreased their price target on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 22nd.

Valneva Price Performance

The company has a current ratio of 1.65, a quick ratio of 1.37 and a debt-to-equity ratio of 1.04. The business has a 50-day moving average of $7.68 and a 200 day moving average of $9.64.

Valneva (NASDAQ:VALN) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). The firm had revenue of $45.12 million for the quarter, compared to analysts’ expectations of $45.06 million. Valneva had a negative net margin of 65.99% and a negative return on equity of 59.48%. As a group, research analysts anticipate that Valneva SE will post 0.11 earnings per share for the current year.

Institutional Trading of Valneva

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS Group AG purchased a new stake in Valneva in the second quarter worth about $31,000. Jane Street Group LLC increased its position in Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after buying an additional 7,664 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in Valneva in the first quarter worth about $858,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.